Drugs / [11C]raclopride
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06977308 | Oct 2026 → Oct 2029 expected | early-onset schizophrenia | New York State Psychiatric Institute | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT02169310 | Nov 2014 → Feb 2024 | traumatic brain injury | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT03190954 Comparator | Aug 2017 → Oct 2025 | opiate dependence | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [11C] Raclopride | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02169310 ↗ |
| Modality | Diagnostic / imaging agent | “dopamine D2 receptor binding potential within mesocorticolimbic subcortical nuclei measured with \[11C\]raclopride PET (Experiment 1)” NCT02169310 ↗ |
| Route | Intravenous | “a chemical is injected through a thin tube into an arm vein” NCT02169310 ↗ |